GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Cogstate Ltd (OTCPK:COGZF) » Definitions » Price-to-Free-Cash-Flow

COGZF (Cogstate) Price-to-Free-Cash-Flow : 31.78 (As of Dec. 13, 2024)


View and export this data going back to 2010. Start your Free Trial

What is Cogstate Price-to-Free-Cash-Flow?

As of today (2024-12-13), Cogstate's share price is $0.731. Cogstate's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Jun. 2024 was $0.02. Hence, Cogstate's Price-to-Free-Cash-Flow Ratio for today is 31.78.

The historical rank and industry rank for Cogstate's Price-to-Free-Cash-Flow or its related term are showing as below:

COGZF' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 14.43   Med: 38.2   Max: 165.98
Current: 36.88

During the past 13 years, Cogstate's highest Price-to-Free-Cash-Flow Ratio was 165.98. The lowest was 14.43. And the median was 38.20.

COGZF's Price-to-Free-Cash-Flow is ranked worse than
72.59% of 394 companies
in the Healthcare Providers & Services industry
Industry Median: 16.33 vs COGZF: 36.88

Cogstate's Free Cash Flow per Share for the six months ended in Jun. 2024 was $0.03. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $0.02.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was -29.50% per year.

During the past 13 years, Cogstate's highest 3-Year average Free Cash Flow per Share Growth Rate was 29.40% per year. The lowest was -29.50% per year. And the median was 21.30% per year.


Cogstate Price-to-Free-Cash-Flow Historical Data

The historical data trend for Cogstate's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cogstate Price-to-Free-Cash-Flow Chart

Cogstate Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Price-to-Free-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 14.02 30.50 - 32.94

Cogstate Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 30.50 - - - 32.94

Competitive Comparison of Cogstate's Price-to-Free-Cash-Flow

For the Health Information Services subindustry, Cogstate's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cogstate's Price-to-Free-Cash-Flow Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Cogstate's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Cogstate's Price-to-Free-Cash-Flow falls into.



Cogstate Price-to-Free-Cash-Flow Calculation

Cogstate's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=0.731/0.023
=31.78

Cogstate's Share Price of today is $0.731.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Cogstate's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Jun. 2024 was $0.02.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

Cogstate  (OTCPK:COGZF) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


Cogstate Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Cogstate's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Cogstate Business Description

Traded in Other Exchanges
Address
161 Collins Street, Level 2, Melbourne, VIC, AUS, 3000
Cogstate Ltd is a cognitive science company. The principal activity of the group is Creation, validation and commercialisation of digital brain health assessments; and Design and provision of quality assurance services in clinical trials, focused on the administration, scoring and recording of conventional brain health assessments and reporting. Its operating segment includes Clinical Trials; Healthcare and Research. The company generates maximum revenue from the Clinical Trials segment. In the clinical trials segment, technology and services are sold to pharmaceutical and biotechnology companies. The company derives revenue from the sale of licensed software and cognitive testing services.